10.89
price up icon4.81%   0.50
after-market Handel nachbörslich: 10.89
loading
Schlusskurs vom Vortag:
$10.39
Offen:
$10.28
24-Stunden-Volumen:
52,210
Relative Volume:
0.57
Marktkapitalisierung:
$279.53M
Einnahmen:
$26.00M
Nettoeinkommen (Verlust:
$-219.71M
KGV:
-0.2187
EPS:
-49.8
Netto-Cashflow:
$-51.37M
1W Leistung:
+5.12%
1M Leistung:
+13.91%
6M Leistung:
-39.20%
1J Leistung:
-55.13%
1-Tages-Spanne:
Value
$10.28
$11.20
1-Wochen-Bereich:
Value
$10.01
$11.78
52-Wochen-Spanne:
Value
$8.46
$26.50

Cartesian Therapeutics Inc Stock (RNAC) Company Profile

Name
Firmenname
Cartesian Therapeutics Inc
Name
Telefon
301-348-8698
Name
Adresse
7495 NEW HORIZON WAY, FREDERICK
Name
Mitarbeiter
66
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
RNAC's Discussions on Twitter

Vergleichen Sie RNAC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RNAC
Cartesian Therapeutics Inc
10.89 279.53M 26.00M -219.71M -51.37M -49.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-19 Eingeleitet BTIG Research Buy
2024-08-06 Eingeleitet TD Cowen Buy
2024-07-02 Herabstufung Oppenheimer Outperform → Perform
2024-06-04 Eingeleitet Oppenheimer Outperform
2024-05-24 Eingeleitet Mizuho Buy
2024-04-23 Bestätigt H.C. Wainwright Buy
2024-04-23 Eingeleitet Leerink Partners Outperform
2023-08-18 Herabstufung SVB Securities Outperform → Market Perform
2022-06-14 Bestätigt Needham Buy
2022-06-06 Eingeleitet SVB Leerink Outperform
2021-06-15 Eingeleitet BTIG Research Buy
2021-01-26 Hochstufung Mizuho Neutral → Buy
2020-10-01 Herabstufung Mizuho Buy → Neutral
2020-10-01 Herabstufung William Blair Outperform → Mkt Perform
2020-06-12 Herabstufung Stifel Buy → Hold
2020-04-28 Eingeleitet H.C. Wainwright Buy
2020-01-29 Eingeleitet Cantor Fitzgerald Overweight
2020-01-21 Eingeleitet William Blair Outperform
2018-06-27 Eingeleitet Janney Buy
2017-03-30 Bestätigt UBS Buy
Alle ansehen

Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten

pulisher
Jun 18, 2025

Myasthenia Gravis Market to Expand Significantly by 2034, States DelveInsight Report | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - The Globe and Mail

Jun 18, 2025
pulisher
Jun 18, 2025

IBM Introduces Industry-First Software to Unify Agentic Governance and Security - The Globe and Mail

Jun 18, 2025
pulisher
Jun 16, 2025

Cartesian Therapeutics holds annual stockholders meeting By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

Cartesian Therapeutics holds annual stockholders meeting - Investing.com

Jun 16, 2025
pulisher
Jun 16, 2025

Cartesian Therapeutics Holds Annual Stockholders Meeting - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Acquired by Bank of America Corp DE - Defense World

Jun 16, 2025
pulisher
Jun 14, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Reduces Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Jun 13, 2025
pulisher
Jun 11, 2025

Equities Analysts Offer Predictions for RNAC FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 05, 2025

Nuveen Asset Management LLC Buys 47,889 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire

Jun 04, 2025
pulisher
Jun 03, 2025

Cartesian Therapeutics Announces New Employment Inducement Grants | RNAC Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Cartesian Therapeutics (RNAC) Issues Inducement Stock Options to New Employees | RNAC Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Cartesian Therapeutics Awards 26,350 Stock Options to Key New Hires in Autoimmune Disease Research - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

H.C. Wainwright maintains buy rating on Cartesian Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 01, 2025

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis - mx.advfn.com

Jun 01, 2025
pulisher
May 30, 2025

Cartesian Therapeutics Enrolls First Participant in Phase 3 Myasthenia Gravis Study - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Cartesian Therapeutics Announces First Participant Enrolled - GlobeNewswire

May 30, 2025
pulisher
May 30, 2025

RNAC Initiates Phase 3 Trial for Myasthenia Gravis Treatment | R - GuruFocus

May 30, 2025
pulisher
May 30, 2025

RNAC Initiates Phase 3 Trial for Myasthenia Gravis Treatment | RNAC Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Cartesian Therapeutics Announces First Participant Enrolled in t - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Cartesian Therapeutics Initiates Phase 3 AURORA Trial of Descartes-08 for Myasthenia Gravis - Nasdaq

May 30, 2025
pulisher
May 30, 2025

Revolutionary CAR-T Treatment Enters Phase 3 Trial After Strong Results in Myasthenia Gravis Patients - Stock Titan

May 30, 2025
pulisher
May 27, 2025

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Benzinga

May 27, 2025
pulisher
May 27, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Lifted by Northern Trust Corp - Defense World

May 27, 2025
pulisher
May 22, 2025

Q1 Earnings Forecast for RNAC Issued By HC Wainwright - Defense World

May 22, 2025
pulisher
May 22, 2025

HC Wainwright Has Bearish Forecast for RNAC Q2 Earnings - Defense World

May 22, 2025
pulisher
May 21, 2025

Weyerhaeuser to Sell Princeton, B.C., Lumber Mill to Gorman Group - The Globe and Mail

May 21, 2025
pulisher
May 20, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

May 20, 2025
pulisher
May 19, 2025

Multiple Myeloma Pipeline 2025: Groundbreaking Clinical - openPR.com

May 19, 2025
pulisher
May 15, 2025

Cantor Fitzgerald Comments on RNAC FY2025 Earnings - Defense World

May 15, 2025
pulisher
May 13, 2025

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor ... - Eagle-Tribune

May 13, 2025
pulisher
May 13, 2025

Wells Fargo & Company MN Acquires 2,568 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

May 13, 2025
pulisher
May 12, 2025

Cartesian Therapeutics (RNAC) Poised for Growth with Strong Phas - GuruFocus

May 12, 2025
pulisher
May 11, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance

May 11, 2025
pulisher
May 11, 2025

Barclays PLC Buys 7,488 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

May 11, 2025
pulisher
May 10, 2025

MetLife Investment Management LLC Invests $119,000 in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

May 10, 2025
pulisher
May 10, 2025

Cartesian Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo

May 10, 2025
pulisher
May 10, 2025

Needham & Company LLC Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World

May 10, 2025
pulisher
May 09, 2025

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC) - The Globe and Mail

May 09, 2025
pulisher
May 09, 2025

Cartesian Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

Needham Maintains Buy Rating on RNAC, Lowers Price Target | RNAC Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

RNAC Reports Strong Q1 Revenue Exceeding Expectations | RNAC Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Cartesian Therapeutics Inc (RNAC) Q1 2025 Earnings: EPS Loss of $(0.68) Beats Estimate, Revenue Surpasses Forecast at $1.1 Million - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Cartesian Therapeutics Announces Upcoming Clinical Trials and Positive Results for Descartes-08 in Autoimmune Diseases - Nasdaq

May 08, 2025
pulisher
May 08, 2025

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire Inc.

May 08, 2025
pulisher
May 06, 2025

Renaissance Technologies LLC Buys New Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

May 06, 2025
pulisher
May 05, 2025

Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey

May 05, 2025

Finanzdaten der Cartesian Therapeutics Inc-Aktie (RNAC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Cartesian Therapeutics Inc-Aktie (RNAC) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
English Emily
Chief Operations Officer
Apr 15 '25
Option Exercise
3.30
7,500
24,750
47,726
SPRINGER TIMOTHY A
Director
Apr 10 '25
Buy
10.47
48,595
508,751
620,175
SPRINGER TIMOTHY A
Director
Apr 09 '25
Buy
9.43
41,782
393,947
571,580
SPRINGER TIMOTHY A
Director
Apr 11 '25
Buy
10.77
36,338
391,455
656,513
SPRINGER TIMOTHY A
Director
Apr 10 '25
Buy
10.47
8,575
89,773
8,637,273
SPRINGER TIMOTHY A
Director
Apr 09 '25
Buy
9.43
7,373
69,517
8,628,698
SPRINGER TIMOTHY A
Director
Apr 11 '25
Buy
10.77
6,412
69,074
8,643,685
SPRINGER TIMOTHY A
Director
Mar 20 '25
Buy
15.59
54,889
855,593
8,621,325
SPRINGER TIMOTHY A
Director
Mar 19 '25
Buy
14.97
20,234
302,962
8,566,436
SPRINGER TIMOTHY A
Director
Mar 18 '25
Buy
14.42
14,740
212,599
8,546,202
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):